Huede Healthtech Co., Ltd.

AI Acute Kidney Injury (AKI) Prediction Software

Joint Commission of Taiwan

The Joint Commission of Taiwan (JCT) is a government-funded and non-profit organization. JCT has committed to promoting healthcare quality and patient safety and using quality management tools and training to help health administrators enhance healthcare quality in the past 2 decades.

JCT established the Health Smart Taiwan (HST), a one-stop portal designed which gathers over 200 successful cases selected from the National Healthcare Quality Award (NHQA). HST catalyzes the existing digital solutions scalable through offering a range of consultations, campaigns, acceleration services etc. It provides integrated services for healthcare institutions to achieve digital transformation, shaping a quality, safe, and efficient healthcare environment.

In this exhibition, HST will feature "Artificial Intelligence in Taiwan's Medical Innovation Technology." You will see more clinical solutions that integrate AI to reduce the workload of healthcare, including enhanced treatment, patient care, disease screening, and pathological interpretation.

Microsoft Taiwan

Microsoft cloud platform, Azure, with its data and artificial intelligence capabilities, in collaboration with Taiwanese medical institutions and partners, is jointly developing innovative smart healthcare solutions to meet the needs and challenges of Taiwan\\\'s healthcare industry.

National Taiwan University

Innovative technologies and solutions from National Taiwan University.

Shine Out Bio Technology

Neuron-targeting Drug Delivery EV Therapy Genetically engineered EV for neurodegenerative diseases.

Shine-On Biomedical Co., Ltd.

1. SOA101: Nano Triple-Specific Dual Immune Checkpoint Antibody • Leading in Asia, the only triple-specific antibody targeting dual immune checkpoints on cancer cells. • Highly specific cancer-targeting HLA-G and PD-L1/HLA-G dual immune checkpoint antibodies can overcome immune escape of cancer cells, reduce drug resistance, and improve therapeutic effectiveness. • A broad-spectrum novel drug for the treatment of various solid tumors. 2. SOA201:EphA10 Triple-Specific T cell Engaging Antibody • Tri-specific antibody targets dual immune cells. • The EphA10 tumor antigen is highly expressed in triple-negative breast cancer (almost negligible expression in normal cells), providing high safety and addressing the therapeutic challenges of lacking targeted drug treatments for triple-negative breast cancer. • Activates and proliferates T cells and NK cells, enhancing anti-cancer efficacy. • A broad-spectrum novel drug for the treatment of various solid tumors. 3. SOB101:Engineered Exosomes with Drug Payloads • Leading in Asia, the only exosome-based anti-cancer drug targeting HLA-G. • Genetically engineered exosomes with anti-HLA-G functionality specifically bind to tumor cells, effectively reducing the dosage of chemotherapy drugs. • Capable of carrying multiple drugs. • A broad-spectrum novel drug for the treatment of various solid tumors. 4. SOB102: Novel Anti-Cancer Exosomal Nucleic Acid Drug • Targeting HLA-G, it effectively and safely deliver the carried nucleic acid drugs and chemotherapy drugs to the tumor. • It can cross the blood-brain barrier and solve the clinical treatment dilemma of drug-resistant glioblastoma multiforme (GBM).

Taichung Armed Forces General Hospital Zhongqing Branch

None

Taichung Veterans General Hospital

-

TAIPEI MEDICAL UNIVERSITY

Established in 1960, over the past century, Taipei Medical University underwent the process of continuous expansion, transformation and innovation. Today, TMU has expanded into a world-class university with 11 Colleges and 1 General Education Center, 6000 students per year, 47,000 alumni around Medical Academic Institute, Medical Industry and six affiliated hospitals which are TMU hospital, Wan Fang Hospital, Shuang Ho Hospital, Hsin Kuo Min Hospital, Tapei Cancer Center and Taipei Neuroscience Institute.
Based on the core value of humanistic empathy, honesty and integrity, innovation, teamwork and social service, TMU is dedicated to excellent teaching, outstanding research, industry-academia collaboration, international participation and social service, in order to integrate clinical resource of affiliated hospitals and meet the visions of translation medicine innovation, biomedical industry development, research advancement and positive social influence. 3 main strategies of future development are below.

TAIPEI MEDICAL UNIVERSITY -HSIN KUO MIN HOSPITAL

--